Dostarlimab: From preclinical investigation to drug approval and future directions

Carlo Maria Cicala, Lucia Musacchio, Giovanni Scambia, Domenica Lorusso

Research output: Contribution to journalArticle


Immune checkpoint blockers (ICB) act by reverting the immunosuppressive phenotype of cancer cells, thus allowing host immune system to generate an immune response to the tumor. One of the key mechanisms targeted by ICB is the PD-1/PD-L1 axis, which lies onto the interaction between the programmed-cell death protein 1 and its ligand, overexpressed in several tumor types. This interaction leads to the inhibition of T-cell proliferation and their apoptosis and exhaustion. Anti-PD-1/PD-L1 monoclonal antibodies are now the mainstay of treatment for several advanced stage tumors. Dostarlimab is a novel IgG4 anti-PD-1 antibody which has yielded remarkable results in mismatch-repair deficient endometrial cancer and locally advanced rectal cancer. This product review will illustrate the preclinical development of dostarlimab and its pharmacological characteristics, the clinical trials published so far and the ongoing clinical investigations.
Original languageEnglish
Pages (from-to)1-10
Number of pages10
Publication statusPublished - 2023


  • Dostarlimab
  • anti-PD-1
  • rectal cancer
  • immunotherapy
  • mismatch repair
  • endometrial cancer


Dive into the research topics of 'Dostarlimab: From preclinical investigation to drug approval and future directions'. Together they form a unique fingerprint.

Cite this